| HALO | PRESS-RELEASE | neutral | 1/10 | Halozyme Therapeutics, Inc. announced it will report its Q3 2026 results on November 5, 2026. | Oct 22, 2026 |
| VCEL | PRESS-RELEASE | neutral | 1/10 | Vericel Corporation announced it will report its Q3 2026 results on November 5, 2026. | Oct 22, 2026 |
| GEVO | PRESS-RELEASE | bullish | 6/10 | Gevo provided a business update highlighting strong growth in its carbon business, which is expected to deliver over $50 | Oct 22, 2026 |
| ARGX | 6-K | bullish | 6/10 | argenx reported strong Q3 2026 results with VYVGART product net sales of $1.7 billion, representing 54% year-over-year g | Oct 22, 2026 |
| MBX | 3 | neutral | 2/10 | Peter Radovich filed an initial Statement of Beneficial Ownership (Form 3) with the SEC, reporting his position as an of | Oct 22, 2026 |
| AGMB | INSIDER-BUY | bullish | 4/10 | Director David R. Epstein purchased 10,000 shares of AgomAb Therapeutics for $89K in two open-market trades on October 2 | Oct 22, 2026 |
| MBX | 8-K | neutral | 2/10 | MBX Biosciences appointed Peter Radovich as an independent Class I director, effective October 20, 2026, expanding the b | Oct 22, 2026 |
| SCNX | PRESS-RELEASE | mixed | 5/10 | Scienture Holdings reported preliminary Q3 2026 revenue of ~$1.22M, up 256% sequentially from Q2's $344K, driven by Arbl | Oct 22, 2026 |
| MIRA | 8-K | bullish | 5/10 | MIRA Pharmaceuticals reported positive preclinical results for MIRA-55, an oral synthetic cannabinoid analog for chronic | Oct 22, 2026 |
| CYRX | PRESS-RELEASE | neutral | 1/10 | Cryoport, Inc. announced it will report its Q3 2026 results on November 5, 2026. | Oct 22, 2026 |
| LENZ | PRESS-RELEASE | neutral | 1/10 | LENZ Therapeutics, Inc. announced it will report its Q3 2026 results on October 29, 2026. | Oct 22, 2026 |
| REPL | PRESS-RELEASE | neutral | 1/10 | Replimune, Inc. announced it will report its fiscal Q2 2027 results on October 28, 2026. | Oct 22, 2026 |
| COLL | PRESS-RELEASE | neutral | 1/10 | Collegium Pharmaceutical, Inc. announced it will report its Q3 2026 results on November 5, 2026. | Oct 22, 2026 |
| KRYS | PRESS-RELEASE | neutral | 1/10 | Krystal Biotech, Inc. announced it will report its Q3 2026 results on November 2, 2026. | Oct 22, 2026 |
| MIRA | PRESS-RELEASE | bullish | 5/10 | MIRA Pharmaceuticals announced positive preclinical results for oral MIRA-55 in a 21-day chronic inflammatory pain model | Oct 22, 2026 |
| SCYX | PRESS-RELEASE | bullish | 7/10 | Scynexis announced positive Phase 1 topline results for IV SCY-247, showing good tolerability and target exposures at 50 | Oct 22, 2026 |
| BNTX | 6-K | neutral | 5/10 | BioNTech announced a clinical trial collaboration with Gilead to evaluate its investigational bispecific immunomodulator | Oct 22, 2026 |
| ABUS | 8-K | bullish | 6/10 | Arbutus Biopharma announced that the FDA has lifted the clinical hold on the IND for AB-101, its oral PD-L1 inhibitor fo | Oct 22, 2026 |
| LNTH | 8-K | neutral | 5/10 | Lantheus disclosed that it and acquirer Curium US Holdings each received a Second Request from the FTC on October 21, 20 | Oct 22, 2026 |
| ABOS | PRESS-RELEASE | neutral | 3/10 | Acumen Pharmaceuticals will present three posters on its Phase 2 ALTITUDE-AD trial of sabirnetug at the CTAD conference | Oct 22, 2026 |
| ABUS | PRESS-RELEASE | bullish | 7/10 | Arbutus Biopharma announced FDA removal of the clinical hold on its IND for AB-101, an oral PD-L1 inhibitor for chronic | Oct 22, 2026 |
| BBIO | PRESS-RELEASE | neutral | 1/10 | BridgeBio Pharma, Inc. announced it will report its Q3 2026 results on October 29, 2026. | Oct 22, 2026 |
| SGMT | 8-K | neutral | 4/10 | Sagimet Biosciences filed an 8-K with an updated investor presentation on October 22, 2026. The presentation highlights | Oct 22, 2026 |
| AZN | 6-K | bullish | 6/10 | AstraZeneca announced that the FDA granted accelerated approval for Ultomiris (ravulizumab) to reduce proteinuria in adu | Oct 22, 2026 |
| PHAR | 6-K | bullish | 6/10 | Pharming Group N.V. released preliminary Q3 2026 revenue above market expectations, with total revenues of ~US$117.6M (+ | Oct 22, 2026 |
| KRRO | 8-K | bullish | 6/10 | Korro Bio reported preclinical data for KRRO-111, its RNA-editing candidate for Alpha-1 Antitrypsin Deficiency (AATD), s | Oct 22, 2026 |
| UTHR | 8-K | neutral | 4/10 | United Therapeutics announced a $2.0 billion share repurchase authorization, effective through October 21, 2027. The com | Oct 22, 2026 |
| BHVN | 8-K | bullish | 6/10 | Biohaven announced that the FDA accepted for review its resubmitted NDA for troriluzole (Vyglxia) in spinocerebellar ata | Oct 22, 2026 |
| CGTX | 8-K | bullish | 7/10 | Cognition Therapeutics announced FDA alignment on key elements of a pivotal Phase 3 trial of zervimesine (CT1812) in dem | Oct 22, 2026 |
| PULM | 425 | neutral | 4/10 | Eos SENOLYTIX presented positive preclinical survival and healthspan data for PTC-2105 at a conference, and launched a p | Oct 22, 2026 |
